Sindhu Malapati

Dr. Sindhu Malapati

University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
VTValentina K Todorova
Valentina K Todorova
GAGohar Azhar
Gohar Azhar
ASAnnjanette Stone
Annjanette Stone
SMSindhu Malapati
Sindhu Malapati
YCYingni Che
Yingni Che
JWJeanne Y Wei
Jeanne Y Wei
Doxorubicin (DOX), a commonly used anticancer agent, causes cardiotoxicity that begins with the first dose and may progress to heart failure years after treatment. An inflammatory response associated with neutrophil recruitment has been recognized as a mechanism of DOX-induced cardiotoxicity. This study aimed to validate mRNA expression of the previously identified biomarkers of DOX-induced cardiotoxicity, PGLYRP1, CAMP, MMP9, and CEACAM8, and to assay their protein expression in the peripheral blood of breast cancer patients. Blood samples from 40 breast cancer patients treated with DOX-based chemotherapy were collected before and after the first chemotherapy cycle and > 2 years after treatment. The protein and gene expression of PGLYRP1/Tag7, CAMP/LL37, MMP9/gelatinase B, and CEACAM8/CD66b were determined using ELISA and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Receiver operating characteristic (ROC) curve analysis was used to determine the diagnostic value of each candidate biomarker. Patients with cardiotoxicity (n = 20) had significantly elevated levels of PGLYRP1, CAMP, MMP9, and CEACAM8 at baseline, after the first dose of DOX-based chemotherapy, and at > 2 years after treatment relative to patients without cardiotoxicity (n = 20). The first dose of DOX induced significantly higher levels of all examined biomarkers in both groups of patients. At > 2 years post treatment, the levels of all but MMP9 dropped below the baseline. There was a good correlation between the expression of mRNA and the target proteins. We demonstrate that circulating levels of PGLYRP1, CAMP, MMP9, and CEACAM8 can predict the cardiotoxicity of DOX. This novel finding may be of value in the early identification of patients at risk for cardiotoxicity.

26 May 2023 in Onco
Verified
Journal Article
Open access
PDF file
FAFnu Amisha
Fnu Amisha
PMParas Malik
Paras Malik
PSPrachi Saluja
Prachi Saluja
NGNitesh Gautam
Nitesh Gautam
TPTanvi Patel
Tanvi Patel
SMSindhu Malapati
Sindhu Malapati
The human epidermal growth factor receptors (HERs) are expressed abundantly in the human body. The tumorigenic potential of HER2/neu is linked to its overexpression, amplification or somatic mutation. The HER2 gene amplification leading to protein overexpression has been reported in 25–30% of breast cancers and 10–30% of gastric/gastroesophageal cancers. While HER2 is a well-documented predictive, prognostic, and therapeutic marker in breast and gastric/gastroesophageal cancers, its relevance has also been demonstrated in multiple other malignancies. In this article, we will conduct an extensive review of current data pertaining to HER2 amplification, overexpression, or mutation in cancers other than breast and gastric cancers.


9 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Shi-Ming TuShi-Ming Tu
Shi-Ming Tu
SSSunny R. Singh
Sunny R. Singh
KAKonstantinos Arnaoutakis
Konstantinos Arnaoutakis
SMSindhu Malapati
Sindhu Malapati
SBSajjad Bhatti
Sajjad Bhatti
LPLouis L. Pisters
Louis L. Pisters
A stem cell theory of cancer considers genetic makeup in the proper cellular context. It is a unified theory of cancer that unites the genome with the epigenome, links the intracellular with the extracellular, and connects the cellular constituents and compartments with the microenvironment. Although it allies with genomic medicine, it is better aligned with integrated medicine. In this perspective, we focus on translational research in cancer care. We expose some intrinsic fallacies in translational research when it relates to the basic principles of the scientific method in the care of patients with genomic medicine versus integrated medicine. We postulate that genomic medicine may be at the root of many failed efforts in drug development and data reproducibility. We propose an alternate heuristic approach that may expedite the development of safe and effective treatments and minimize the generation of unproductive pharmaceutical products and nonreproducible experimental results. Importantly, a heuristic approach emphasizes the role of a pertinent scientific theory and distinguishes therapy development from drug development, such that we discover not only useful drugs but also better ways to use them in order to optimize patient care and maximize clinical outcomes.

14 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Shi-Ming TuShi-Ming Tu
Shi-Ming Tu
ATAnup K. Trikannad
Anup K. Trikannad
SVSruthi Vellanki Sruthi Vellanki
Sruthi Vellanki Sruthi Vellanki
MHMunawwar Hussain
Munawwar Hussain
NMNazish Malik
Nazish Malik
OAOmar T. Atiq
Omar T. Atiq
Although immunotherapy has revolutionized cancer care, there is still an urgent need to enhance its efficacy and ensure its safety. A correct cancer theory and proper scientific method empower pertinent cancer research and enable effective and efficient drug versus therapy development for patient care. In this perspective, we revisit the concept of immune privilege in a cancer cell versus normal cell, as well as in a cancer stem cell versus normal stem cell. We re-examine whether effective immunotherapies are efficacious due to their anti-cancer and/or immune modulatory mechanisms. We reassess why checkpoint inhibitors (CPIs) are not equal. We reconsider whether one can attribute the utility of immunotherapy to specific cancer subtypes and its futility to certain tumor/immune compartments, components, and microenvironments. We propose ways and means to advance immunotherapy beyond CPIs by combining anti-PD1/L1 with various other treatment modalities according to an appropriate scientific theory, e.g., stem cell origin of cancer, and based on available clinical evidence, e.g., randomized clinical trials. We predict that a stem cell theory of cancer will facilitate the design of better and safer immunotherapy with improved selection of its use for the right patient with the right cancer type at the right time to optimize clinical benefits and minimize potential toxic effects and complications.

1 October 2023 in JCO Oncology Practice
Verified
Journal Article
Closed access
SMSindhu Malapati
Sindhu Malapati
DIDame Idossa
Dame Idossa
SSSunny R.K. Singh
Sunny R.K. Singh
ZWZihan Wei
Zihan Wei
LKLauren Kiel
Lauren Kiel
NDNarjust Duma
Narjust Duma
Oncology trainee/early-career faculty survey shows inadequate parental leave/lactation policies #parentpenalty